Atria Investments LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 1.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,474 shares of the biopharmaceutical company’s stock after selling 4,136 shares during the period. Atria Investments LLC’s holdings in Pfizer were worth $8,180,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Earnest Partners LLC purchased a new position in Pfizer in the 4th quarter valued at about $105,000. First Dallas Securities Inc. purchased a new position in shares of Pfizer during the 4th quarter worth about $118,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in shares of Pfizer during the 4th quarter worth about $118,000. Delpha Capital Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $126,000. Finally, Delphi Private Advisors LLC lifted its holdings in shares of Pfizer by 84.3% during the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,600 shares during the period. Institutional investors and hedge funds own 69.43% of the company’s stock.
PFE opened at $36.38 on Tuesday. The company has a market cap of $217.34 billion, a P/E ratio of 13.73, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. Pfizer Inc. has a 1 year low of $32.32 and a 1 year high of $39.43. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. The firm had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 EPS. analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 1st. Shareholders of record on Friday, May 11th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.74%. The ex-dividend date of this dividend was Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is 51.32%.
In other Pfizer news, CEO Ian C. Read sold 132,312 shares of the stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director W Don Cornwell sold 5,223 shares of the stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $36.40, for a total transaction of $190,117.20. The disclosure for this sale can be found here. Insiders sold 156,535 shares of company stock valued at $5,647,222 in the last ninety days. 0.06% of the stock is owned by corporate insiders.
Several research analysts have recently weighed in on the stock. Morningstar set a $43.50 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, May 2nd. Jefferies Financial Group reiterated a “neutral” rating and set a $39.00 price objective on shares of Pfizer in a report on Monday, May 14th. Berenberg Bank reiterated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, April 11th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Wednesday, April 11th. Finally, Morgan Stanley reiterated a “buy” rating and set a $43.00 price objective on shares of Pfizer in a report on Monday, June 11th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average target price of $40.27.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.